Abbott’s Libre Duo 10-Day System Receives FDA Authorization as First Wearable Continuous Glucose-Ketone Monitor in U.S.

September 13, 2026

Diabetes Education Services USA

Overview

Abbott has secured FDA authorization for its Libre Duo 10 Day Continuous Dual Glucose-Ketone Monitoring System, making it the first wearable device in the U.S. and globally to continuously monitor both glucose and ketone levels for individuals aged 2 and older with diabetes. This system aims to prevent diabetic ketoacidosis (DKA) through real-time trend data and alerts, supported by robust clinical evidence from six studies involving over 600 participants. The breakthrough significantly enhances diabetes management by offering continuous, non-invasive insight into two critical biomarkers, improving patient safety and enabling proactive care.

In Depth

Key Findings

Abbott announced on September 6, 2026, that its Libre Duo 10 Day Continuous Dual Glucose-Ketone Monitoring System received authorization from the U.S. Food and Drug Administration (FDA). This landmark approval marks the first wearable device in the United States, and globally, capable of continuously monitoring both glucose and ketone levels simultaneously for individuals aged 2 and older with diabetes. This innovation is poised to significantly enhance comprehensive self-management and, crucially, aid in the early detection and prevention of diabetic ketoacidosis (DKA), a severe diabetes complication.

Technical / Clinical Details

The Libre Duo system functions by continuously measuring glucose and ketone levels in the interstitial fluid for up to 10 days via a small, easily applied sensor. It integrates with a dedicated smartphone application that provides real-time trend data, historical insights, and customizable alerts for high or low glucose, as well as elevated ketone levels. Clinical validation included six comprehensive studies involving over 600 participants, demonstrating high accuracy comparable to traditional blood glucose meters and an excellent safety profile. This continuous data empowers patients to understand the interplay between their glucose fluctuations and ketone trends, facilitating more informed decisions regarding insulin dosages, diet, and exercise adjustments.

Background & Context

Effective diabetes management necessitates stringent glucose control alongside vigilance against DKA, a life-threatening condition caused by insulin deficiency leading to increased ketone production. Historically, ketone monitoring has relied on inconvenient and intermittent methods like urine or finger-prick blood tests, making continuous oversight challenging. The FDA authorization of Libre Duo addresses a critical unmet need in diabetes care, particularly for individuals with Type 1 diabetes and those at high risk of DKA during illness. This development further propels the evolution of Continuous Glucose Monitoring (CGM) technology, extending its utility beyond glucose alone.

Strategic Significance & Outlook

The FDA authorization of Libre Duo represents a pivotal shift in diabetes care, offering patients unprecedented insights into their metabolic state and enabling proactive responses to potentially dangerous physiological changes, thereby improving quality of life. For healthcare providers, this continuous, dual-biomarker data facilitates more precise and personalized treatment strategies, potentially reducing emergency room visits and hospitalizations due to DKA, and subsequently lowering healthcare costs. Abbott’s commitment to broad market accessibility and ongoing patient education signals a future where integrated, continuous monitoring becomes a standard component of holistic health management, particularly in chronic disease states.

Source: https://diabetesed.net/a-new-paradigm-in-diabetes-care-fda-authorizes-the-worlds-first-continuous-glucose-ketone-monitor/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.